Clinical trials: sponsored by Institut Pasteur
- Sponsor Institut Pasteur
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Congenital Hearing Loss, Bilateral Cochlear Implants
Investigating the Neural Oscillatory Features for Limited Access to Oral Language in Deaf Children With Early Bilateral Cochlear Implantation
Children with severe-to-profound congenital hearing loss often experience significant language development challenges. While cochlear implants (CIs) can restore auditory input, outcomes vary widely, even among those who receive…
- Trial name
- ICO (NCT07739433)
- Volunteers
- 150 people
- Sponsor
- Institut Pasteur
Diarrhea, Infantile
Study on the Association Between Vitamin C Deficiency and Diarrhea in Children
Diarrheal disease is the second leading cause of death in children under five, althought it is both preventable and treatable. The causative factors of diarrheal diseases vary a lot from region to region (bacteria, viruses…
- Trial name
- VITAL (NCT05328037)
- Testing
- Blood sample collection
- Where
- 3 sites in Central African Republic, France and 1 more
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Autism Spectrum Disorder
A Rhythmic and Auditory Approach for Children With Autism Spectrum Disorders (ASD)
The aim of this study is to assess the effectiveness of a rhythmic auditory training program in improving language skills in children with Autism Spectrum Disorder (ASD) who have a language acquisition disorder.
- Trial name
- THETABOOST (NCT07303413)
- Testing
- EEG recording, Picture recognition test
- Volunteers
- 24 people
- Sponsor
- Institut Pasteur
Snake Bites, Antivenins
Evaluation of Anti-venoms Serum in Africa
There is little or no assessment under real-use conditions of the efficacy and the tolerance in the short, medium and long term of the antivenoms currently on the market and used in the treatment of snake bites.
- Conditions
- Snake Bites, Antivenins, Snake Venoms
- Trial name
- ESAA (NCT03326492)
- Testing
- Antivenom serum Inoserp Pan-Africa® injection
- Where
- 13 sites in Cameroon
- Volunteers
- 474 people
- Sponsor
- Institut Pasteur
Simian Foamy Virus Infection (Disorder)
Simian Foamy Virus Transmission to Humans
About three quarters of the viral agents that have emerged recently in humans are considered to originate from other animals. These viruses have often evolved and spread into the human population through various mechanisms after…
- Trial name
- NCT03225794
- Testing
- Simian foamy virus Infection
- Where
- Cameroon
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Listeriosis
Genetic Susceptibility to Listeriosis
Listeriosis is a rare, severe foodborne infection, responsible for severe invasive infections. It occurs in the great majority of cases in elderly patients and / or patients with comorbidities, with a deficit of innate or…
- Trial name
- Listeria-GEN (NCT03357536)
- Testing
- Human biological samples
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Speech
Elicitation of Steady-state Audiovisual Responses in 6- and 10-month-old Infants
The goal of this study is to investigate the preferential responses of speech neural systems in infants. The main question it aims to answer is to determine whether the oscillatory synchronization capacity is associated with…
- Trial name
- AV-SSR-I (NCT06282289)
- Testing
- Magnetoencephalography (MEG), Cognition development questionnaire
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Dyslexia
Evaluation of Speech Rhythm Training in Dyslexic Readers Aged 7 to 9 Years
Studies of dyslexia have shown altered oscillatory activity in the low gamma band (~25-35 Hz) in the left auditory cortex. Neural oscillations around 30 Hz constitute the basic sampling rate of speech, from which the ability to…
- Trial name
- RnDys (NCT05996497)
- Testing
- behavioral measures, Electrophysiological measures, Training 1
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Institut Pasteur
Tuberculosis
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
The objective of this project is to demonstrate safety, immunogenicity and improved efficacy of the new live attenuated M. tuberculosis vaccine called MTBVAC in a Phase 3 efficacy trial in HIV-uninfected infants born to…
- Trial name
- MTBVACN3 (NCT04975178)
- Testing
- MTBVAC, BCG
- Where
- South Africa
- Volunteers
- 7,120 people, healthy volunteers welcome
- Sponsor
- Biofabri, S.L
Malaria, Bacterial Co-infection
Host Immunity, Plasmodium and Pathogens Co-Infections
Few studies have focused on malaria co-infections, mainly caused by Plasmodium falciparum, occurring mainly in children under 5 years of age in sub-Saharan Africa.
- Trial name
- HIPPI (NCT06769815)
- Testing
- Blood sample, Urine sample, oropharyngeal sample
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Bordetella Pertussis, Whooping Cough
Impact of Bacterial Expression and Immune Response in the Severity of Pertussis
The resurgence of pertussis is associated with an evolutionary mechanism under the pressure of current acellular vaccines, with a possible impact on vaccine effectiveness and disease expression.
- Trial name
- PERT-SEVEREII (NCT05897879)
- Testing
- Nasopharyngeal swab, Blood samples
- Where
- 14 sites in France
- Volunteers
- 210 people
- Sponsor
- Institut Pasteur
Arbovirus Infections, Dengue
Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, especially in tropical and sub-tropical countries.
- Conditions
- Arbovirus Infections, Dengue, Zika, Chikungunya
- Trial name
- DENWOLUTION (NCT04615364)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Institut Pasteur
Arbovirus Disease, Zika
Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
The Pacific region is facing several emerging and neglected diseases notably mosquito-borne diseases as malaria or arboviroses among which dengue, Ross River, chikungunya and Zika.
- Conditions
- Arbovirus Disease, Zika, Dengue, Ross River
- Trial name
- PIANO (NCT05153018)
- Testing
- Blood collection
- Where
- 4 sites in Vanuatu
- Volunteers
- 1,122 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Healthy
A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a
A study among adults, children and infants in Kenya to determine if a new type of glycoconjugate vaccine incorporating a synthetic carbohydrate component is safe and induces immunity against Shigella.
- Trial name
- GlycoShig3 (NCT04602975)
- Testing
- Injection SF2A-TT15 10 µg Adjuvanted, Injection SF2A-TT15 10 µg, Injection SF2A-TT15 2 µg Adjuvanted
- Where
- Kenya
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Monkeypox Virus Infection
A One Health Study of Monkeypox Human Infection
This multidisciplinary project aim to understand the epidemiology of the monkeypox in Central African Republic through the identification of the animal reservoir, the clinical and epidemiological description of the human…
- Trial name
- AFRIPOX (NCT05058898)
- Testing
- blood samples, Scabs and pus samples
- Where
- Central African Republic
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Hepatitis B
Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule
Hepatitis B virus (HBV) infection is an important global health problem, and the WHO adopted a strategy to eliminate HBV infection as a public health threat by the year 2030.
- Trial name
- NEOVAC2BK (NCT04029454)
- Testing
- birth dose vaccination against hepatitis B strategy
- Where
- 2 sites in Burkina Faso
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
SARS (Severe Acute Respiratory Syndrome), COVID-19
Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France
On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO).
- Trial name
- CORSER (NCT04325646)
- Testing
- Human Biological samples
- Where
- 21 sites in France
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
SARS (Severe Acute Respiratory Syndrome), Covid19
Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19]
An initial retrospective epidemiological investigation was conducted in a city north of France after the diagnosis of the first case of COVID-19 on February 2020.
- Trial name
- COVID-OISE (NCT04644159)
- Testing
- Human biological samples
- Where
- 2 sites in France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Rabies
Immunity Persistence After Abridged Intradermal Rabies PEP
After exposure, rabies can be prevented in almost 100% of cases by the administration of sufficient and timely post-exposure prophylaxis (PEP).
- Trial name
- RESIST-3 (NCT04829630)
- Testing
- rabies vaccine
- Where
- 2 sites in Cambodia, Madagascar
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Plague, Plague, Bubonic
Yersinia Pestis Lateral Flow Immunoassay for Blood Samples
Plague is a deadly but highly treatable disease caused by the bacterium Y. pestis. Due to the historical development of Y. pestis as a bioweapon by several nation states, it is listed by the US as a potential bioweapon that could…
- Conditions
- Plague, Plague, Bubonic, Plague, Pneumonic, Yersinia Pestis Plague
- Trial name
- SMARTPRT (NCT04688996)
- Testing
- Lateral Flow Assay for Pathogens of the Plague
- Where
- 2 sites in United States, Madagascar
- Volunteers
- 500 people
- Sponsor
- Brimrose Technology Corporation